Symbols / SVRA
SVRA Chart
About
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.15B |
| Enterprise Value | 1.30B | Income | -115.64M | Sales | — |
| Book/sh | 0.44 | Cash/sh | 0.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 59 | IPO | — |
| P/E | — | Forward P/E | -14.10 | PEG | — |
| P/S | — | P/B | 12.94 | P/C | — |
| EV/EBITDA | -10.79 | EV/Sales | — | Quick Ratio | 7.52 |
| Current Ratio | 7.65 | Debt/Eq | 31.60 | LT Debt/Eq | — |
| EPS (ttm) | -0.53 | EPS next Y | -0.40 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -39.67% |
| ROE | -78.74% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 203.47M |
| Shs Float | 116.71M | Short Float | 12.00% | Short Ratio | 13.82 |
| Short Interest | — | 52W High | 7.00 | 52W Low | 1.89 |
| Beta | 0.32 | Avg Volume | 2.46M | Volume | 1.75M |
| Target Price | $10.81 | Recom | Strong_buy | Prev Close | $5.70 |
| Price | $5.64 | Change | -1.05% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.81
Mean price target
2. Current target
$5.66
Latest analyst target
3. DCF / Fair value
$-4.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.66
Low
$9.00
High
$16.00
Mean
$10.81
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-23 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-12-18 | main | Wells Fargo | Overweight → Overweight | $9 |
| 2025-11-14 | main | Oppenheimer | Outperform → Outperform | $9 |
| 2025-11-13 | main | Citizens | Market Outperform → Market Outperform | $10 |
| 2025-10-23 | main | JMP Securities | Market Outperform → Market Outperform | $11 |
| 2025-09-09 | main | Guggenheim | Buy → Buy | $11 |
| 2025-09-08 | main | Oppenheimer | Outperform → Outperform | $8 |
| 2025-09-03 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-08-15 | main | Oppenheimer | Outperform → Outperform | $6 |
| 2025-08-15 | up | HC Wainwright & Co. | Neutral → Buy | $5 |
| 2025-06-01 | main | Oppenheimer | Outperform → Outperform | $5 |
| 2025-05-29 | down | HC Wainwright & Co. | Buy → Neutral | $2 |
| 2025-05-28 | main | Evercore ISI Group | In-Line → In-Line | $2 |
| 2025-05-28 | main | Guggenheim | Buy → Buy | $8 |
| 2025-05-28 | main | Wells Fargo | Overweight → Overweight | $7 |
| 2025-03-31 | main | Evercore ISI Group | In-Line → Hold | $3 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-12-20 | init | Wells Fargo | — → Overweight | $8 |
| 2024-12-19 | reit | JMP Securities | Market Outperform → Market Outperform | $9 |
| 2024-11-13 | main | HC Wainwright & Co. | Buy → Buy | $6 |
- SVRA stock rises after hours as FDA grants priority review for lung disorder therapy - MSN Sat, 21 Feb 2026 09
- FDA fast-tracks potential first drug for rare lung disease - Stock Titan Fri, 20 Feb 2026 21
- Savara, Inc. (SVRA) Stock Analysis: Biotech Player With An 89% Upside Potential - DirectorsTalk Interviews Sat, 21 Feb 2026 06
- Is FDA Priority Review for MOLBREEVI Reshaping the Investment Case for Savara (SVRA)? - simplywall.st Mon, 23 Feb 2026 21
- $SVRA stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Wed, 19 Nov 2025 08
- Savara Stock: A High-Risk Opportunity (NASDAQ:SVRA) - Seeking Alpha Sun, 16 Nov 2025 08
- Savara Announces New Employment Inducement Grant - Business Wire Fri, 13 Feb 2026 21
- Savara (NASDAQ:SVRA) Shares Up 6.8% - Here's Why - MarketBeat hu, 12 Feb 2026 08
- Assessing Savara (SVRA) Valuation Following Recent Share Price Momentum - Yahoo Finance Fri, 14 Nov 2025 08
- Citizens reiterates Savara stock rating on likely FDA approval By Investing.com - Investing.com South Africa ue, 24 Feb 2026 00
- Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 150% Potential Upside - DirectorsTalk Interviews Fri, 24 Oct 2025 07
- $SVRA stock is up 17% today. Here's what we see in our data. - Quiver Quantitative Fri, 28 Nov 2025 08
- GSA Capital Partners LLP Has $1.33 Million Stock Holdings in Savara Inc. $SVRA - MarketBeat hu, 19 Feb 2026 10
- A rare lung disease may get new option after MOLBREEVI FDA filing - Stock Titan Mon, 22 Dec 2025 08
- Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough - Yahoo Finance Sat, 23 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1807 | 3180 | — | Conversion of Exercise of derivative security at price 1.76 per share. | MCCRACKEN JOSEPH S | Director | — | 2026-02-13 00:00:00 | D |
| 1 | 32000 | — | — | Stock Gift at price 0.00 per share. | LOWRANCE DAVID L. CPA | Chief Financial Officer | — | 2025-12-16 00:00:00 | D |
| 2 | 128995 | — | — | Stock Gift at price 0.00 per share. | PAULS MATTHEW | Chief Executive Officer | — | 2025-12-16 00:00:00 | D |
| 3 | 23629 | — | — | Stock Gift at price 0.00 per share. | PAULS MATTHEW | Chief Executive Officer | — | 2025-12-10 00:00:00 | D |
| 4 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | HAWKINS RICHARD JAMES | Director | — | 2025-12-09 00:00:00 | D |
| 5 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | ELAM NEVAN C | Director | — | 2025-12-09 00:00:00 | D |
| 6 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | MCCRACKEN JOSEPH S | Director | — | 2025-12-09 00:00:00 | D |
| 7 | 40000 | — | — | Stock Award(Grant) at price 0.00 per share. | VAN ES-JOHANSSON AN | Director | — | 2025-12-09 00:00:00 | D |
| 8 | 5860 | 8556 | — | Conversion of Exercise of derivative security at price 1.46 per share. | ELAM NEVAN C | Director | — | 2025-12-02 00:00:00 | D |
| 9 | 5860 | 8556 | — | Conversion of Exercise of derivative security at price 1.46 per share. | HAWKINS RICHARD JAMES | Director | — | 2025-11-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -102.32M | -59.21M | -37.86M | -40.27M |
| TotalUnusualItems | 51.00K | 76.00K | -19.00K | -99.00K |
| TotalUnusualItemsExcludingGoodwill | 51.00K | 76.00K | -19.00K | -99.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -95.88M | -54.70M | -38.15M | -43.01M |
| ReconciledDepreciation | 130.00K | 77.00K | 167.00K | 367.00K |
| EBITDA | -102.27M | -59.13M | -37.88M | -40.37M |
| EBIT | -102.40M | -59.21M | -38.04M | -40.73M |
| NetInterestIncome | 6.47M | 4.44M | -88.00K | -2.28M |
| InterestExpense | 88.00K | 2.28M | ||
| InterestIncome | 6.47M | 4.44M | ||
| NormalizedIncome | -95.93M | -54.77M | -38.13M | -42.91M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -95.88M | -54.70M | -38.15M | -43.01M |
| TotalExpenses | 102.40M | 59.21M | 38.04M | 40.63M |
| TotalOperatingIncomeAsReported | -103.20M | -60.01M | -38.84M | -41.48M |
| DilutedAverageShares | 198.19M | 165.20M | 152.77M | 133.92M |
| BasicAverageShares | 198.19M | 165.20M | 152.77M | 133.92M |
| DilutedEPS | -0.48 | -0.33 | -0.25 | -0.32 |
| BasicEPS | -0.48 | -0.33 | -0.25 | -0.32 |
| DilutedNIAvailtoComStockholders | -95.88M | -54.70M | -38.15M | -43.01M |
| NetIncomeCommonStockholders | -95.88M | -54.70M | -38.15M | -43.01M |
| NetIncome | -95.88M | -54.70M | -38.15M | -43.01M |
| NetIncomeIncludingNoncontrollingInterests | -95.88M | -54.70M | -38.15M | -43.01M |
| NetIncomeContinuousOperations | -95.88M | -54.70M | -38.15M | -43.01M |
| PretaxIncome | -95.88M | -54.70M | -38.15M | -43.01M |
| OtherIncomeExpense | 51.00K | 76.00K | -19.00K | -99.00K |
| GainOnSaleOfSecurity | 51.00K | 76.00K | -19.00K | -99.00K |
| NetNonOperatingInterestIncomeExpense | 6.47M | 4.44M | -88.00K | -2.28M |
| TotalOtherFinanceCost | -4.44M | 88.00K | ||
| InterestExpenseNonOperating | 88.00K | 2.28M | ||
| InterestIncomeNonOperating | 6.47M | 4.44M | ||
| OperatingIncome | -102.40M | -59.21M | -38.04M | -40.63M |
| OperatingExpense | 102.40M | 59.21M | 38.04M | 40.63M |
| OtherTaxes | -797.00K | -797.00K | -796.00K | -844.00K |
| DepreciationAmortizationDepletionIncomeStatement | 130.00K | 77.00K | 31.00K | 136.00K |
| DepreciationAndAmortizationInIncomeStatement | 130.00K | 77.00K | 31.00K | 136.00K |
| ResearchAndDevelopment | 78.03M | 44.26M | 27.88M | 28.99M |
| SellingGeneralAndAdministration | 25.04M | 15.67M | 10.93M | 12.35M |
| GeneralAndAdministrativeExpense | 25.04M | 15.67M | 10.93M | 12.35M |
| OtherGandA | 25.04M | 15.67M | 10.93M | 12.35M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 172.42M | 138.14M | 114.05M | 114.04M |
| ShareIssued | 172.42M | 138.14M | 114.05M | 114.04M |
| NetDebt | 11.49M | |||
| TotalDebt | 26.73M | 26.49M | 26.14M | 25.79M |
| TangibleBookValue | 161.11M | 129.41M | 97.12M | 133.22M |
| InvestedCapital | 198.07M | 166.72M | 133.86M | 170.15M |
| WorkingCapital | 187.41M | 155.35M | 123.09M | 150.34M |
| NetTangibleAssets | 161.11M | 129.41M | 97.12M | 133.22M |
| CapitalLeaseObligations | 116.00K | 143.00K | 64.00K | 135.00K |
| CommonStockEquity | 171.45M | 140.37M | 107.78M | 144.50M |
| TotalCapitalization | 198.07M | 166.72M | 133.86M | 161.82M |
| TotalEquityGrossMinorityInterest | 171.45M | 140.37M | 107.78M | 144.50M |
| StockholdersEquity | 171.45M | 140.37M | 107.78M | 144.50M |
| GainsLossesNotAffectingRetainedEarnings | -750.00K | -271.00K | -605.00K | 5.00K |
| OtherEquityAdjustments | -750.00K | -271.00K | -605.00K | 5.00K |
| RetainedEarnings | -489.25M | -393.37M | -338.67M | -300.52M |
| AdditionalPaidInCapital | 661.28M | 533.87M | 446.94M | 444.90M |
| CapitalStock | 173.00K | 140.00K | 116.00K | 116.00K |
| CommonStock | 173.00K | 140.00K | 116.00K | 116.00K |
| TotalLiabilitiesNetMinorityInterest | 41.43M | 37.19M | 32.00M | 32.10M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 26.71M | 26.59M | 26.13M | 17.44M |
| OtherNonCurrentLiabilities | 87.00K | 247.00K | 54.00K | 117.00K |
| LongTermDebtAndCapitalLeaseObligation | 26.62M | 26.35M | 26.08M | 17.32M |
| LongTermDebt | 26.62M | 26.35M | 26.08M | 17.32M |
| CurrentLiabilities | 14.72M | 10.60M | 5.87M | 14.66M |
| CurrentDebtAndCapitalLeaseObligation | 116.00K | 143.00K | 64.00K | 8.47M |
| CurrentCapitalLeaseObligation | 116.00K | 143.00K | 64.00K | 135.00K |
| CurrentDebt | 8.33M | |||
| OtherCurrentBorrowings | 8.33M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.02M | 4.05M | 2.37M | 2.53M |
| PayablesAndAccruedExpenses | 9.59M | 6.41M | 3.44M | 3.67M |
| CurrentAccruedExpenses | 5.05M | 2.90M | 2.10M | 2.22M |
| Payables | 4.54M | 3.50M | 1.33M | 1.44M |
| AccountsPayable | 4.54M | 3.50M | 1.33M | 1.44M |
| TotalAssets | 212.88M | 177.56M | 139.78M | 176.60M |
| TotalNonCurrentAssets | 10.74M | 11.62M | 10.82M | 11.60M |
| OtherNonCurrentAssets | 242.00K | 387.00K | 116.00K | 251.00K |
| GoodwillAndOtherIntangibleAssets | 10.34M | 10.96M | 10.66M | 11.27M |
| OtherIntangibleAssets | 10.34M | 10.96M | 10.66M | 11.27M |
| NetPPE | 165.00K | 270.00K | 51.00K | 73.00K |
| AccumulatedDepreciation | -2.16M | -2.01M | -1.92M | -2.08M |
| GrossPPE | 2.33M | 2.28M | 1.97M | 2.15M |
| Leases | 333.00K | 333.00K | 145.00K | 153.00K |
| OtherProperties | 1.87M | 1.84M | 1.77M | 1.85M |
| MachineryFurnitureEquipment | 120.00K | 110.00K | 61.00K | 151.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 202.13M | 165.95M | 128.95M | 165.00M |
| OtherCurrentAssets | 455.00K | 280.00K | 71.00K | 356.00K |
| PrepaidAssets | 4.31M | 2.34M | 2.05M | 2.33M |
| Receivables | 1.04M | 1.00M | 954.00K | 1.14M |
| TaxesReceivable | 1.04M | 1.00M | 954.00K | 1.14M |
| CashCashEquivalentsAndShortTermInvestments | 196.33M | 162.32M | 125.88M | 161.17M |
| OtherShortTermInvestments | 181.20M | 135.73M | 73.78M | 127.16M |
| CashAndCashEquivalents | 15.13M | 26.59M | 52.10M | 34.01M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -89.11M | -51.36M | -34.56M | -40.14M |
| RepurchaseOfCapitalStock | -995.00K | -1.21M | -3.00K | -78.00K |
| RepaymentOfDebt | 0.00 | -26.35M | 0.00 | |
| IssuanceOfDebt | 0.00 | 26.44M | 0.00 | |
| IssuanceOfCapitalStock | 118.17M | 83.70M | 0.00 | 122.23M |
| CapitalExpenditure | -25.00K | -296.00K | -9.00K | -57.00K |
| InterestPaidSupplementalData | 2.12M | 2.04M | 1.61M | 1.97M |
| EndCashPosition | 15.13M | 26.59M | 52.10M | 34.01M |
| BeginningCashPosition | 26.59M | 52.10M | 34.01M | 22.88M |
| EffectOfExchangeRateChanges | -5.00K | -118.00K | -90.00K | -137.00K |
| ChangesInCash | -11.45M | -25.40M | 18.18M | 11.27M |
| FinancingCashFlow | 117.58M | 82.78M | 87.00K | 120.81M |
| CashFlowFromContinuingFinancingActivities | 117.58M | 82.78M | 87.00K | 120.81M |
| NetOtherFinancingCharges | 46.00K | |||
| ProceedsFromStockOptionExercised | 354.00K | 283.00K | 2.00K | -1.35M |
| NetCommonStockIssuance | 117.18M | 82.50M | -3.00K | 122.15M |
| CommonStockPayments | -995.00K | -1.21M | -3.00K | -78.00K |
| CommonStockIssuance | 118.17M | 83.70M | 0.00 | 122.23M |
| NetIssuancePaymentsOfDebt | 0.00 | 88.00K | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | 88.00K | 0.00 | |
| LongTermDebtPayments | 0.00 | -26.35M | 0.00 | |
| LongTermDebtIssuance | 0.00 | 26.44M | 0.00 | |
| InvestingCashFlow | -39.94M | -57.12M | 52.65M | -69.46M |
| CashFlowFromContinuingInvestingActivities | -39.94M | -57.12M | 52.65M | -69.46M |
| NetInvestmentPurchaseAndSale | -39.92M | -56.82M | 52.65M | -69.40M |
| SaleOfInvestment | 165.00M | 137.40M | 142.07M | 91.67M |
| PurchaseOfInvestment | -204.92M | -194.22M | -89.42M | -161.07M |
| NetIntangiblesPurchaseAndSale | 0.00 | |||
| PurchaseOfIntangibles | 0.00 | |||
| NetPPEPurchaseAndSale | -25.00K | -296.00K | -9.00K | -57.00K |
| PurchaseOfPPE | -25.00K | -296.00K | -9.00K | -57.00K |
| OperatingCashFlow | -89.09M | -51.06M | -34.55M | -40.08M |
| CashFlowFromContinuingOperatingActivities | -89.09M | -51.06M | -34.55M | -40.08M |
| ChangeInWorkingCapital | 1.83M | 4.07M | 960.00K | -2.85M |
| ChangeInOtherCurrentLiabilities | 0.00 | -44.00K | ||
| ChangeInOtherCurrentAssets | 11.00K | -12.00K | -57.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 4.20M | 4.54M | -319.00K | -1.76M |
| ChangeInPayable | 4.20M | 4.54M | -319.00K | -1.76M |
| ChangeInAccountPayable | 4.20M | 4.54M | -319.00K | -1.76M |
| ChangeInPrepaidAssets | -2.38M | -456.00K | 1.34M | -1.04M |
| OtherNonCashItems | 271.00K | 271.00K | 334.00K | 449.00K |
| StockBasedCompensation | 9.86M | 4.18M | 2.04M | 3.26M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | |||
| AmortizationOfSecurities | -5.44M | -4.98M | 75.00K | 1.60M |
| DepreciationAmortizationDepletion | 130.00K | 77.00K | 167.00K | 367.00K |
| DepreciationAndAmortization | 130.00K | 77.00K | 167.00K | 367.00K |
| Depreciation | 175.00K | 167.00K | 367.00K | |
| OperatingGainsLosses | 145.00K | 22.00K | 19.00K | 99.00K |
| NetForeignCurrencyExchangeGainLoss | 0.00 | -76.00K | 19.00K | 99.00K |
| GainLossOnSaleOfPPE | 145.00K | 98.00K | ||
| NetIncomeFromContinuingOperations | -95.88M | -54.70M | -38.15M | -43.01M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SVRA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|